Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of a one-year supervised physical activity program on long-term cancer-related fatigue and mediating effects of the gut microbiota in metastatic testicular cancer patients: protocol of the prospective multicentre, randomized controlled phase-III STARTER trial.
Noh H, Anota A, Mongondry R, Meyrand R, Dupuis C, Schiffler C, Marijnen P, Rinaldi S, Lachuer J, Keski-Rahkonen P, Gunter MJ, Fléchon A, Fervers B, Pérol O. Noh H, et al. Among authors: flechon a. BMC Cancer. 2024 Jan 15;24(1):84. doi: 10.1186/s12885-024-11824-7. BMC Cancer. 2024. PMID: 38225551 Free PMC article.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Hegemann M, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Del Muro XG, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T; RANGE study investigators. Petrylak DP, et al. Among authors: flechon a. Lancet. 2017 Nov 18;390(10109):2266-2277. doi: 10.1016/S0140-6736(17)32365-6. Epub 2017 Sep 12. Lancet. 2017. PMID: 28916371 Clinical Trial.
Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial.
Pfister C, Harter V, Allory Y, Radvanyi F, Culine S; VESPER Trial Investigators. Pfister C, et al. Contemp Clin Trials Commun. 2020 Jan 30;17:100536. doi: 10.1016/j.conctc.2020.100536. eCollection 2020 Mar. Contemp Clin Trials Commun. 2020. PMID: 32083220 Free PMC article.
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer.
Loriot Y, Kalebasty AR, Fléchon A, Jain RK, Gupta S, Bupathi M, Beuzeboc P, Palmbos P, Balar AV, Kyriakopoulos CE, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zhou H, Grivas P, Barthélémy P, Bangs R, Tagawa ST. Loriot Y, et al. Among authors: flechon a. Future Oncol. 2024;20(23):1621-1631. doi: 10.2217/fon-2023-1030. Epub 2024 Jun 5. Future Oncol. 2024. PMID: 38682560 Free PMC article.
Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study.
Powles T, Csőszi T, Loriot Y, Matsubara N, Geczi L, Cheng SY, Fradet Y, Alva A, Oudard S, Vulsteke C, Morales-Barrera R, Fléchon A, Gunduz S, Liu CC, Moreno BH, Bavle A, Özgüroğlu M. Powles T, et al. Among authors: flechon a. Clin Genitourin Cancer. 2024 Nov 1;23(1):102261. doi: 10.1016/j.clgc.2024.102261. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39642775
French AFU Cancer Committee Guidelines-Update 2024-2026: Penile cancer.
Neuville P, Escoffier A, Savoie PH, Fléchon A, Branger N, Rocher L, Camparo P, Murez T, Rouprêt M. Neuville P, et al. Among authors: flechon a. Fr J Urol. 2024 Nov;34(12):102736. doi: 10.1016/j.fjurol.2024.102736. Fr J Urol. 2024. PMID: 39581662 Review.
Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Bossi A, Foulon S, Maldonado X, Sargos P, MacDermott R, Kelly P, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Salem N, Calabro F, Berdah JF, Hasbini A, Silva M, Boustani J, Ribault H, Fizazi K; PEACE-1 investigators. Bossi A, et al. Among authors: flechon a. Lancet. 2024 Nov 23;404(10467):2065-2076. doi: 10.1016/S0140-6736(24)01865-8. Lancet. 2024. PMID: 39580202 Clinical Trial.
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.
Fléchon A, Morales-Barrera R, Powles T, Alva A, Özgüroğlu M, Csöszi T, Loriot Y, Rodriguez-Vida A, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Gunduz S, Mamtani R, Yu EY, Montesa Pino A, Anido U, Sendur MAN, Gravis G, Révész J, Kostorov V, Huillard O, Ma J, Rajasagi M, Vajdi A, Lunceford J, Cristescu R, Imai K, Homet Moreno B, Matsubara N. Fléchon A, et al. Clin Cancer Res. 2024 Dec 2;30(23):5353-5364. doi: 10.1158/1078-0432.CCR-23-3518. Clin Cancer Res. 2024. PMID: 39475359 Free PMC article. Clinical Trial.
245 results